Completed PHASE1 INTERVENTIONAL 3-arm NCT02738489

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Advanced Melanoma

Interventions SHR-1210

Updated 9 times since 2017 Last updated: Feb 23, 2023 Started: Apr 13, 2016 Primary completion: Jan 8, 2020 Completion: Jan 8, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02738489, this PHASE1 trial focuses on Advanced Melanoma and remains completed. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 9 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2023 — Jul 2024 [monthly]

Completed PHASE1
Sep 2022 — Mar 2023 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jan 2021 — Sep 2022 [monthly]

Unknown Status PHASE1

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Apr 2018 — Jun 2018 [monthly]

Unknown Status PHASE1

Status: Enrolling By Invitation → Unknown Status
Feb 2017 — Apr 2018 [monthly]

Enrolling By Invitation PHASE1
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE1

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China